Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature
Abstract SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is base...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 2019-09, Vol.58 (9), p.1534-1546 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1546 |
|---|---|
| container_issue | 9 |
| container_start_page | 1534 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 58 |
| creator | Bonhomme, Olivier André, Béatrice Gester, Fanny de Seny, Dominique Moermans, Catherine Struman, Ingrid Louis, Renaud Malaise, Michel Guiot, Julien |
| description | Abstract
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease. |
| doi_str_mv | 10.1093/rheumatology/kez230 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6736409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/rheumatology/kez230</oup_id><sourcerecordid>2256106818</sourcerecordid><originalsourceid>FETCH-LOGICAL-c582t-1721023830d49db9c41ea145e55f28e44bf9ef07f6352803e2edb212c2d9c8c3</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS0EomXgCZCQJTZs0trXTsZhgQQVFKRKbLq3HOcm49aJB9sZNDw9ptOOCitWvpK_c-7PIeQ1Z2ecteI8bnCZTA4-jPvzW_wFgj0hp1w2UDEh4OmxBnlCXqR0wxiruVDPyYng0EIj61OiP7kwmXiLMVE307RPGSdnabIeY0guVSalYJ3J2BcgFy677IynfplH2ruEJuF7GnHn8CcNA80bpN4V0OQl4kvybDA-4av7d0Wuv3y-vvhaXX2__Hbx8aqytYJc8TVwBkIJ1su271orORoua6zrARRK2Q0tDmw9NKIGxQQC9h1wsNC3VlmxIh8Ottulm7C3OOdovN5GV5bb62Cc_vtndhs9hp1u1qKR5ZorIg4G3uGIOsTO6R3cCe_qxY_aWN2hBmiUBsmA8aJ6d982hh8Lpqwnlyx6b2YMSyps3XDWKK4K-vYf9CYscS43KWZr2UrelFmOY9hy_BRxOK7Amf6Tun6cuj6kXlRvHm9_1DzEXICzAxCW7X85_gaBKr_T</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474941667</pqid></control><display><type>article</type><title>Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature</title><source>MEDLINE</source><source>AUTh Library subscriptions: Oxford University Press</source><source>Alma/SFX Local Collection</source><creator>Bonhomme, Olivier ; André, Béatrice ; Gester, Fanny ; de Seny, Dominique ; Moermans, Catherine ; Struman, Ingrid ; Louis, Renaud ; Malaise, Michel ; Guiot, Julien</creator><creatorcontrib>Bonhomme, Olivier ; André, Béatrice ; Gester, Fanny ; de Seny, Dominique ; Moermans, Catherine ; Struman, Ingrid ; Louis, Renaud ; Malaise, Michel ; Guiot, Julien</creatorcontrib><description>Abstract
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease.</description><identifier>ISSN: 1462-0324</identifier><identifier>ISSN: 1462-0332</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kez230</identifier><identifier>PMID: 31292645</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Acute-Phase Proteins - metabolism ; Biomarkers ; Biomarkers - blood ; Cardiovascular & respiratory systems ; Connective Tissue Growth Factor - blood ; Cytokines - blood ; Disease Progression ; fibrosis ; Human health sciences ; Humans ; ILD ; Immunosuppression ; Literature reviews ; Lung diseases ; Lung Diseases, Interstitial - diagnosis ; Lung Diseases, Interstitial - etiology ; Matrix Metalloproteinases - blood ; Mucin-1 - blood ; Prognosis ; Pulmonary fibrosis ; Pulmonary Surfactant-Associated Protein A - blood ; Pulmonary Surfactant-Associated Protein D - blood ; Reviews ; Sciences de la santé humaine ; Scleroderma ; Scleroderma, Systemic - complications ; Scleroderma, Systemic - diagnosis ; SSc-ILD ; Systemic sclerosis ; Systèmes cardiovasculaire & respiratoire</subject><ispartof>Rheumatology (Oxford, England), 2019-09, Vol.58 (9), p.1534-1546</ispartof><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c582t-1721023830d49db9c41ea145e55f28e44bf9ef07f6352803e2edb212c2d9c8c3</citedby><cites>FETCH-LOGICAL-c582t-1721023830d49db9c41ea145e55f28e44bf9ef07f6352803e2edb212c2d9c8c3</cites><orcidid>0000-0003-4006-2014</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31292645$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonhomme, Olivier</creatorcontrib><creatorcontrib>André, Béatrice</creatorcontrib><creatorcontrib>Gester, Fanny</creatorcontrib><creatorcontrib>de Seny, Dominique</creatorcontrib><creatorcontrib>Moermans, Catherine</creatorcontrib><creatorcontrib>Struman, Ingrid</creatorcontrib><creatorcontrib>Louis, Renaud</creatorcontrib><creatorcontrib>Malaise, Michel</creatorcontrib><creatorcontrib>Guiot, Julien</creatorcontrib><title>Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>Abstract
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease.</description><subject>Acute-Phase Proteins - metabolism</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular & respiratory systems</subject><subject>Connective Tissue Growth Factor - blood</subject><subject>Cytokines - blood</subject><subject>Disease Progression</subject><subject>fibrosis</subject><subject>Human health sciences</subject><subject>Humans</subject><subject>ILD</subject><subject>Immunosuppression</subject><subject>Literature reviews</subject><subject>Lung diseases</subject><subject>Lung Diseases, Interstitial - diagnosis</subject><subject>Lung Diseases, Interstitial - etiology</subject><subject>Matrix Metalloproteinases - blood</subject><subject>Mucin-1 - blood</subject><subject>Prognosis</subject><subject>Pulmonary fibrosis</subject><subject>Pulmonary Surfactant-Associated Protein A - blood</subject><subject>Pulmonary Surfactant-Associated Protein D - blood</subject><subject>Reviews</subject><subject>Sciences de la santé humaine</subject><subject>Scleroderma</subject><subject>Scleroderma, Systemic - complications</subject><subject>Scleroderma, Systemic - diagnosis</subject><subject>SSc-ILD</subject><subject>Systemic sclerosis</subject><subject>Systèmes cardiovasculaire & respiratoire</subject><issn>1462-0324</issn><issn>1462-0332</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhS0EomXgCZCQJTZs0trXTsZhgQQVFKRKbLq3HOcm49aJB9sZNDw9ptOOCitWvpK_c-7PIeQ1Z2ecteI8bnCZTA4-jPvzW_wFgj0hp1w2UDEh4OmxBnlCXqR0wxiruVDPyYng0EIj61OiP7kwmXiLMVE307RPGSdnabIeY0guVSalYJ3J2BcgFy677IynfplH2ruEJuF7GnHn8CcNA80bpN4V0OQl4kvybDA-4av7d0Wuv3y-vvhaXX2__Hbx8aqytYJc8TVwBkIJ1su271orORoua6zrARRK2Q0tDmw9NKIGxQQC9h1wsNC3VlmxIh8Ottulm7C3OOdovN5GV5bb62Cc_vtndhs9hp1u1qKR5ZorIg4G3uGIOsTO6R3cCe_qxY_aWN2hBmiUBsmA8aJ6d982hh8Lpqwnlyx6b2YMSyps3XDWKK4K-vYf9CYscS43KWZr2UrelFmOY9hy_BRxOK7Amf6Tun6cuj6kXlRvHm9_1DzEXICzAxCW7X85_gaBKr_T</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Bonhomme, Olivier</creator><creator>André, Béatrice</creator><creator>Gester, Fanny</creator><creator>de Seny, Dominique</creator><creator>Moermans, Catherine</creator><creator>Struman, Ingrid</creator><creator>Louis, Renaud</creator><creator>Malaise, Michel</creator><creator>Guiot, Julien</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>Q33</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4006-2014</orcidid></search><sort><creationdate>20190901</creationdate><title>Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature</title><author>Bonhomme, Olivier ; André, Béatrice ; Gester, Fanny ; de Seny, Dominique ; Moermans, Catherine ; Struman, Ingrid ; Louis, Renaud ; Malaise, Michel ; Guiot, Julien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c582t-1721023830d49db9c41ea145e55f28e44bf9ef07f6352803e2edb212c2d9c8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute-Phase Proteins - metabolism</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular & respiratory systems</topic><topic>Connective Tissue Growth Factor - blood</topic><topic>Cytokines - blood</topic><topic>Disease Progression</topic><topic>fibrosis</topic><topic>Human health sciences</topic><topic>Humans</topic><topic>ILD</topic><topic>Immunosuppression</topic><topic>Literature reviews</topic><topic>Lung diseases</topic><topic>Lung Diseases, Interstitial - diagnosis</topic><topic>Lung Diseases, Interstitial - etiology</topic><topic>Matrix Metalloproteinases - blood</topic><topic>Mucin-1 - blood</topic><topic>Prognosis</topic><topic>Pulmonary fibrosis</topic><topic>Pulmonary Surfactant-Associated Protein A - blood</topic><topic>Pulmonary Surfactant-Associated Protein D - blood</topic><topic>Reviews</topic><topic>Sciences de la santé humaine</topic><topic>Scleroderma</topic><topic>Scleroderma, Systemic - complications</topic><topic>Scleroderma, Systemic - diagnosis</topic><topic>SSc-ILD</topic><topic>Systemic sclerosis</topic><topic>Systèmes cardiovasculaire & respiratoire</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonhomme, Olivier</creatorcontrib><creatorcontrib>André, Béatrice</creatorcontrib><creatorcontrib>Gester, Fanny</creatorcontrib><creatorcontrib>de Seny, Dominique</creatorcontrib><creatorcontrib>Moermans, Catherine</creatorcontrib><creatorcontrib>Struman, Ingrid</creatorcontrib><creatorcontrib>Louis, Renaud</creatorcontrib><creatorcontrib>Malaise, Michel</creatorcontrib><creatorcontrib>Guiot, Julien</creatorcontrib><collection>Oxford University Press Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonhomme, Olivier</au><au>André, Béatrice</au><au>Gester, Fanny</au><au>de Seny, Dominique</au><au>Moermans, Catherine</au><au>Struman, Ingrid</au><au>Louis, Renaud</au><au>Malaise, Michel</au><au>Guiot, Julien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>58</volume><issue>9</issue><spage>1534</spage><epage>1546</epage><pages>1534-1546</pages><issn>1462-0324</issn><issn>1462-0332</issn><eissn>1462-0332</eissn><abstract>Abstract
SSc is a rare disease of unknown origin associated with multiple organ involvement. One of the major complications that drives the mortality of SSc patients is interstitial lung disease. The course of SSc-interstitial lung disease progression has a wide spectrum. Since the treatment is based on aggressive immunosuppression it should not be given to stable or non-progressing disease. The correct identification of disease with high risk of progression remains a challenge for early therapeutic intervention, and biomarkers remain urgently needed. In fact, eight categories of biomarkers have been identified and classified according to the different biological pathways involved. The purpose of this article is to describe the main biomarkers thought to be of interest with clinical value in the diagnosis and prognosis of SSc-interstitial lung disease.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31292645</pmid><doi>10.1093/rheumatology/kez230</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-4006-2014</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 2019-09, Vol.58 (9), p.1534-1546 |
| issn | 1462-0324 1462-0332 1462-0332 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6736409 |
| source | MEDLINE; AUTh Library subscriptions: Oxford University Press; Alma/SFX Local Collection |
| subjects | Acute-Phase Proteins - metabolism Biomarkers Biomarkers - blood Cardiovascular & respiratory systems Connective Tissue Growth Factor - blood Cytokines - blood Disease Progression fibrosis Human health sciences Humans ILD Immunosuppression Literature reviews Lung diseases Lung Diseases, Interstitial - diagnosis Lung Diseases, Interstitial - etiology Matrix Metalloproteinases - blood Mucin-1 - blood Prognosis Pulmonary fibrosis Pulmonary Surfactant-Associated Protein A - blood Pulmonary Surfactant-Associated Protein D - blood Reviews Sciences de la santé humaine Scleroderma Scleroderma, Systemic - complications Scleroderma, Systemic - diagnosis SSc-ILD Systemic sclerosis Systèmes cardiovasculaire & respiratoire |
| title | Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T16%3A33%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20in%20systemic%20sclerosis-associated%20interstitial%20lung%20disease:%20review%20of%20the%20literature&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Bonhomme,%20Olivier&rft.date=2019-09-01&rft.volume=58&rft.issue=9&rft.spage=1534&rft.epage=1546&rft.pages=1534-1546&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kez230&rft_dat=%3Cproquest_pubme%3E2256106818%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2474941667&rft_id=info:pmid/31292645&rft_oup_id=10.1093/rheumatology/kez230&rfr_iscdi=true |